Balaxi Pharmaceuticals Limited

NSE BALAXI.NS

Balaxi Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2024: 18.92%

Balaxi Pharmaceuticals Limited EBITDA Margin is 18.92% for the year ending March 31, 2024, a 7.58% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Balaxi Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2023 was 17.59%, a -10.94% change year over year.
Balaxi Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2022 was 19.75%, a 2.25% change year over year.
Balaxi Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2021 was 19.32%, a 6.95% change year over year.
Balaxi Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2020 was 18.06%, a 10.01% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: BALAXI.NS

Balaxi Pharmaceuticals Limited

CEO	Ashish Maheshwari
IPO Date	Dec. 2, 2015
Location	India
Headquarters	MAPS Towers
Employees	51
Sector	Consumers Staples
Industries Retail & Wholesale Cleaning Supplies Consumer Packaged Goods Drugstores & Retail Pharmacies Glass Hardware & Electronics Non-Alcoholic Beverages Pharmaceuticals

Description

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.

Key trends

Past 5 years